Search results
Earnings call: Protalix BioTherapeutics Q1 2024 financial results By Investing.com
Investing.com· 6 days agoThe company announced the expansion of their Phase I study for PRX-115, a recombinant uricase...
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
Clinical Trials Arena via Yahoo Finance· 22 hours agoPhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
CBS 47 Fresno· 1 day agoThis cash position, and other secured funding sources, provide a runway through Q1 2026. In Q1 2024, Ryvu announced the initiation of two Phase II studies ...
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Pharmaceutical Technology via Yahoo Finance· 30 minutes agoThe approval is based on results from the open-label, global, multicentre, single-arm Phase II...
KRAS inhibitors: The next frontier beckons
Pharmaceutical Technology via Yahoo Finance· 2 hours agoT cell responses were seen in 84% of all patients and in 100% of those in the two highest-dose cohorts, including those who received the recommended ...
Raheem Morris: Kirk Cousins is "pretty much full-go" in Phase II
ProFootball Talk on NBC Sports via Yahoo Sports· 6 days agoSpeaking to the media at the start of rookie minicamp on Friday, head coach Raheem Morris said that...
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 hours agoHaving robust preclinical, clinical and manufacturing data to date, we submitted, in January, a formidable information package to the FDA, along with a request for an end of Phase< ...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 3 days agoMeanwhile, Regeneron has completed a Phase II trial of its candidate mibavademab in lipodystrophy...
Recce Pharmaceuticals doses first participants in next cohort Phase I/II UTI/Urosepsis rapid...
Proactive Investors· 1 day agoRecce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has dosed the first participants in the next cohort...
Earnings call: Acumen Pharmaceuticals reports progress in ALTITUDE-AD study By Investing.com
Investing.com· 2 days agoAcumen Pharmaceuticals, in its Q1 2024 earnings call, detailed the initiation of the ALTITUDE-AD ...
